1. Home
  2. News
  3. Xizang Weixinkang Pharmaceutical Co., Ltd.
  4. Announcement on Signing Exclusive License Agreement
More Xizang Weixinkang Pharmaceutical Co., Ltd. news
Xizang Weixinkang Pharmaceutical Co., Ltd.SSE: 603676

Announcement on Signing Exclusive License Agreement

Sep 28, 2024 · Issued by Xizang Weixinkang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Sep 28, 2024 · 5 pages · Chinese

On 6ix: 6ix.com/news/announcement-on-signing-exclusive-license-agreement

Xizang Weixinkang Pharmaceutical Co., Ltd. on 6ix

Earlier from Xizang Weixinkang Pharmaceutical

  • Announcement on Expiration of Shareholding Reduction by Directors and Senior Management Members through Call Auction and the Result of Unreduced SharesSep 13, 2024
  • Announcement on Obtaining Notice of Approval for Drug Clinical Trials by SubsidiarySep 7, 2024

Later from Xizang Weixinkang Pharmaceutical

  • Announcement on Resolution of the 11th Meeting of the 3rd Board of SupervisorsOct 29, 2024
  • Announcement on Progress in Repurchasing SharesNov 5, 2024
  • Announcement on Implementation of Dividend Distribution for Q1-Q3 2024Nov 6, 2024
  • Announcement on Withdrawal of Drug Registration Application by the SubsidiaryNov 15, 2024
  • Announcement on Initially Repurchasing Shares through Call AuctionNov 26, 2024
All Xizang Weixinkang Pharmaceutical news releases↗

Follow Xizang Weixinkang Pharmaceutical into a list and get an email when it puts out news.

Follow Xizang Weixinkang Pharmaceutical
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer